NCT03541941View on ClinicalTrials.gov

Exparel vs. Bupivacaine Hydrochloride vs. Placebo for Hernia Repair

PHASE4CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

July 3, 2018

Primary Completion Date

December 19, 2019

Study Completion Date

December 19, 2019

Conditions
Analgesia, Postoperative
Interventions
DRUG

Exparel

Solution of: 266mg of Bupivacaine Liposome Injectable Suspension (Exparel) mixed with 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block

DRUG

Bupivacaine Hcl 0.25% Inj

Solution of: 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block

DRUG

Placebo

Normal saline administered intraoperatively through a transversus abdominis plane (TAP) block

Trial Locations (1)

44195

Cleveland Clinic Comprehensive Hernia Center, Cleveland

Sponsors
All Listed Sponsors
collaborator

Pacira Pharmaceuticals, Inc

INDUSTRY

lead

The Cleveland Clinic

OTHER

NCT03541941 - Exparel vs. Bupivacaine Hydrochloride vs. Placebo for Hernia Repair | Biotech Hunter | Biotech Hunter